Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Oral everolimus inhibits neointimal proliferation in prosthetic pulmonary valved stents in pigs.

Kuehne T, Pietzner K, Lehmkuhl HB, Gelernter D, Peters B, Krueger JJ, Meinus C, Klimes K, Brinkert F, Ewert P, Berger F.

J Heart Valve Dis. 2008 Jul;17(4):465-72.

PMID:
18751477
2.

Oral everolimus inhibits in-stent neointimal growth.

Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R.

Circulation. 2002 Oct 29;106(18):2379-84.

3.

Experimental efficacy of an everolimus eluting cobalt chromium stent.

Carter AJ, Brodeur A, Collingwood R, Ross S, Gibson L, Wang CA, Haller S, Coleman L, Virmani R.

Catheter Cardiovasc Interv. 2006 Jul;68(1):97-103.

PMID:
16755598
4.

Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries.

Waksman R, Pakala R, Baffour R, Hellinga D, Seabron R, Kolodgie F, Virmani R.

Cardiovasc Revasc Med. 2006 Jul-Sep;7(3):179-84.

PMID:
16945826
5.

Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model.

Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ.

Circulation. 2001 Sep 4;104(10):1188-93.

6.

Advances in experimental percutaneous pulmonary valve replacement.

Attmann T, Jahnke T, Quaden R, Boening A, Muller-Hulsbeck S, Cremer J, Lutter G.

Ann Thorac Surg. 2005 Sep;80(3):969-75.

PMID:
16122466
7.

Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent-mediated delivery of everolimus.

Zhao HQ, Nikanorov A, Virmani R, Schwartz LB.

J Vasc Surg. 2012 Dec;56(6):1680-8. doi: 10.1016/j.jvs.2012.04.022.

8.

Everolimus attenuates neointimal hyperplasia in cultured human saphenous vein grafts.

Semsroth S, Stigler RG, Bernecker OY, Ruttmann-Ulmer E, Troppmair J, Macfelda K, Bonatti JO, Laufer G.

Eur J Cardiothorac Surg. 2009 Mar;35(3):515-20. doi: 10.1016/j.ejcts.2008.11.035.

PMID:
19167904
9.

Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia.

Windecker S, Mayer I, De Pasquale G, Maier W, Dirsch O, De Groot P, Wu YP, Noll G, Leskosek B, Meier B, Hess OM; Working Group on Novel Surface Coating of Biomedical Devices (SCOL)..

Circulation. 2001 Aug 21;104(8):928-33.

10.

Percutaneous heart valve replacement: histology and calcification characteristics of biological valved stents in juvenile sheep.

Attmann T, Quaden R, Freistedt A, K├Ânig C, Cremer J, Lutter G.

Cardiovasc Pathol. 2007 May-Jun;16(3):165-70.

PMID:
17502246
11.

Polymer stent coating for prevention of neointimal hyperplasia.

Billinger M, Buddeberg F, Hubbell JA, Elbert DL, Schaffner T, Mettler D, Windecker S, Meier B, Hess OM.

J Invasive Cardiol. 2006 Sep;18(9):423-6; discussion 427.

PMID:
16954581
12.

Stent-mediated methylprednisolone delivery reduces macrophage contents and in-stent neointimal formation.

Wang L, Salu K, Verbeken E, Bosmans J, Van de Werf F, De Scheerder I, Huang Y.

Coron Artery Dis. 2005 Jun;16(4):237-43.

PMID:
15915076
13.

Direct-access valve replacement a novel approach for off-pump valve implantation using valved stents.

Huber CH, Cohn LH, von Segesser LK.

J Am Coll Cardiol. 2005 Jul 19;46(2):366-70.

14.

Stent-based nitric oxide delivery reducing neointimal proliferation in a porcine carotid overstretch injury model.

Hou D, Narciso H, Kamdar K, Zhang P, Barclay B, March KL.

Cardiovasc Intervent Radiol. 2005 Jan-Feb;28(1):60-5.

PMID:
15719180
15.

Transapical mitral valved stent implantation.

Lozonschi L, Quaden R, Edwards NM, Cremer J, Lutter G.

Ann Thorac Surg. 2008 Sep;86(3):745-8. doi: 10.1016/j.athoracsur.2008.05.039.

PMID:
18721555
16.

Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation.

Muller DW, Golomb G, Gordon D, Levy RJ.

Coron Artery Dis. 1994 May;5(5):435-42.

PMID:
7921375
17.

[Transcatheter pulmonary valve replacement in sheep: 6-month evaluation of self-expanding valved stents].

Zong GJ, Bai Y, Qin YW, Jiang HB, Zhang H, Yao YL, Zou YQ, Zhao XX, Wu H, Huang XM.

Zhonghua Xin Xue Guan Bing Za Zhi. 2008 Feb;36(2):151-5. Chinese.

PMID:
19099955
18.

Percutaneous pulmonary polyurethane valved stent implantation.

Metzner A, Iino K, Steinseifer U, Uebing A, de Buhr W, Cremer J, Lutter G.

J Thorac Cardiovasc Surg. 2010 Mar;139(3):748-52. doi: 10.1016/j.jtcvs.2009.08.013.

19.

Stent-based tempamine delivery on neointimal formation in a porcine coronary model.

Huang Y, Wang L, Li S, Liu X, Lee K, Verbeken E, van de Werf F, de Scheerder I.

Acute Card Care. 2006;8(4):210-6.

PMID:
17162547
20.

Valved stents for transapical pulmonary valve replacement.

Huber CH, Hurni M, Tsang V, von Segesser LK.

J Thorac Cardiovasc Surg. 2009 Apr;137(4):914-8. doi: 10.1016/j.jtcvs.2008.09.024.

Items per page

Supplemental Content

Support Center